About this Research Topic
Pancreatic cancer has a mortality rate of over 90%, making it the deadliest of all cancers. Although research towards novel treatment modalities have increased during the past 20 years, the prognosis remains largely the same. Nanotherapeutics are attractive candidates to treat pancreatic cancer, due to their prolonged drug release and rapid cell internalization. They also reduce systemic toxicity of chemotherapeutics and can be targeted to specific cell types, making them an attractive treatment model.
Although cancer nanotherapeutics have made remarkable headway in treating a variety of cancers in clinical trials, little progress has been made in the pancreatic cancer field. Although nanodelivery of chemotherapeutic agents initially showed promising results in animal studies, the prognosis for pancreatic patients has not significantly improved. This is thought to be largely due to chemotherapeutic resistance caused by pancreatic cancer stem cells.
We propose that generating novel nanoparticles that both target pancreatic cancer stem cells, while delivering chemotherapeutic drug(s), would be more effective at reducing tumor load, invasiveness, and drug resistance, thus improving the prognosis of pancreatic cancer patients.
This Research Topic seeks to investigate novel treatments for pancreatic cancer, whether testing new drugs, or using novel combinations of drugs with commonly used therapeutics. We welcome contributions spanning a wide range of topics, including but not limited to nanotherapeutics, pancreatic cancer, pancreatic cancer stem cells, pancreatic cancer vaccines, and novel cell or animal models.
We welcome the following article types: Brief Research Report, Case Report, Clinical Trial, Correction, Hypothesis & Theory, Methods, Original Research, Policy and Practice Reviews, Study Protocol, Systematic Review, and Technology and Code.
Although cancer nanotherapeutics have made remarkable headway in treating a variety of cancers in clinical trials, little progress has been made in the pancreatic cancer field. Although nanodelivery of chemotherapeutic agents initially showed promising results in animal studies, the prognosis for pancreatic patients has not significantly improved. This is thought to be largely due to chemotherapeutic resistance caused by pancreatic cancer stem cells.
We propose that generating novel nanoparticles that both target pancreatic cancer stem cells, while delivering chemotherapeutic drug(s), would be more effective at reducing tumor load, invasiveness, and drug resistance, thus improving the prognosis of pancreatic cancer patients.
This Research Topic seeks to investigate novel treatments for pancreatic cancer, whether testing new drugs, or using novel combinations of drugs with commonly used therapeutics. We welcome contributions spanning a wide range of topics, including but not limited to nanotherapeutics, pancreatic cancer, pancreatic cancer stem cells, pancreatic cancer vaccines, and novel cell or animal models.
We welcome the following article types: Brief Research Report, Case Report, Clinical Trial, Correction, Hypothesis & Theory, Methods, Original Research, Policy and Practice Reviews, Study Protocol, Systematic Review, and Technology and Code.
Keywords: Nanoparticles, Pancreatic Cancer, Cancer Stem Cells, Immunotherapy-Resistance
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
